Inter-individual variability of in vivo CYP2D6 activity in different genotypes

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 4, 2012, Pages 405-413

  Chiba, Koji ^a   Kato, Motohiro ^b   Ito, Takashi ^c   Suwa, Toshio ^a   Sugiyama, Yuichi ^d  

^a KEIO UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c DAIICHI SANKYO CO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP2D6; Dextromethorphan; Drug discovery; Inter individual variability; Monte Carlo simulation; Pharmacogenetics; Physiologically based pharmacokinetics

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; RISPERIDONE; TOLTERODINE;

AREA UNDER THE CURVE; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; CYP2D6 GENE; DATA ANALYSIS; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; ETHNIC DIFFERENCE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IN VIVO STUDY; MATHEMATICAL MODEL; MONTE CARLO METHOD; NULL ALLELE; POPULATION GENETICS; SYSTEMATIC REVIEW;

EID: 84865376767     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-078     Document Type: Article

References (48)

1. Barter, Z. E., Bayliss, M. K., Beaune, P. H., Boobis, A. R., Carlile, D. J., Edwards, R. J., Houston, J. B., Lake, B. G., Lipscomb, J. C., Pelkonen, O. R., Tucker, G. T. and Rostami-Hodjegan, A.: Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab., 8: 33-45 (2007).
2. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G. and Rostami-Hodjegan, A.: The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol., 5: 211-223 (2009).
3. Kato, M., Chiba, K., Ito, T., Koue, T. and Sugiyama, Y.: Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. Drug Metab. Pharmacokinet., 25: 367-378 (2010).
4. Ito, T., Kato, M., Chiba, K., Okazaki, O. and Sugiyama, Y.: Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. Drug Metab. Pharmacokinet., 25: 243-253 (2010).
5. Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B. and Li, C.: Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 35: 1292-1300 (2007).
6. Zhou, S. F.: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 48: 689-723 (2009).
7. Llerena, A., Dorado, P. and Penas-Lledo, E. M.: Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics, 10: 17-28 (2009).
8. Frank, D., Jaehde, U. and Fuhr, U.: Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol., 63: 321-333 (2007).
9. Myrand, S. P., Sekiguchi, K., Man, M. Z., Lin, X., Tzeng, R. Y., Teng, C. H., Hee, B., Garrett, M., Kikkawa, H., Lin, C. Y., Eddy, S. M., Dostalik, J., Mount, J., Azuma, J., Fujio, Y., Jang, I. J., Shin, S. G., Bleavins, M. R., Williams, J. A., Paulauskis, J. D. and Wilner, K. D.: Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther., 84: 347-361 (2008).
10. Roberts, M. S. and Rowland, M.: Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J. Pharm. Pharmacol., 38: 177-181 (1986).
11. Naritomi, Y., Terashita, S., Kagayama, A. and Sugiyama, Y.: Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos., 31: 580-588 (2003).
12. Shibata, Y., Takahashi, H., Chiba, M. and Ishii, Y.: A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. Drug Metab. Pharmacokinet., 23: 328-339 (2008).
13. Schadel, M., Wu, D., Otton, S. V., Kalow, W. and Sellers, E. M.: Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J. Clin. Psychopharmacol., 15: 263-269 (1995).
14. Wynne, H. A., Cope, L. H., Mutch, E., Rawlins, M. D., Woodhouse, K. W. and James, O. F.: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology, 9: 297-301 (1989).
15. Nagai, N., Kawakubo, T., Kaneko, F., Ishii, M., Shinohara, R., Saito, Y., Shimamura, H., Ohnishi, A. and Ogata, H.: Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population. Biopharm. Drug Dispos., 17: 421-433 (1996).
16. Gaedigk, A., Simon, S. D., Pearce, R. E., Bradford, L. D., Kennedy, M. J. and Leeder, J. S.: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther., 83: 234-242 (2008).
17. Hu, O. Y., Tang, H. S., Lane, H. Y., Chang, W. H. and Hu, T. M.: Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J. Pharmacol. Exp. Ther., 285: 955-960 (1998).
18. Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G. and Fuselli, S.: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics, 17: 93-101 (2007).
19. Zanger, U. M., Fischer, J., Raimundo, S., Stuven, T., Evert, B. O., Schwab, M. and Eichelbaum, M.: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 11: 573-585 (2001).
20. Wennerholm, A., Johansson, I., Massele, A. Y., Lande, M., Alm, C., Aden-Abdi, Y., Dahl, M. L., Ingelman-Sundberg, M., Bertilsson, L. and Gustafsson, L. L.: Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9: 707-714 (1999).
21. Lötsch, J., Rohrbacher, M., Schmidt, H., Doehring, A., Brockmoller, J. and Geisslinger, G.: Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain, 144: 119-124 (2009).
22. Vetticaden, S. J., Cabana, B. E., Prasad, V. K., Purich, E. D., Jonkman, J. H., de Zeeuw, R., Ball, L., Leeson, L. J. and Braun, R. L.: Phenotypic differences in dextromethorphan metabolism. Pharm. Res., 6: 13-19 (1989).
23. Yeh, G. C., Tao, P. L., Ho, H. O., Lee, Y. J., Chen, J. Y. and Sheu, M. T.: Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J. Biomed. Sci., 10: 552-564 (2003).
24. Nakashima, D., Takama, H., Ogasawara, Y., Kawakami, T., Nishitoba, T., Hoshi, S., Uchida, E. and Tanaka, H.: Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J. Clin. Pharmacol., 47: 1311-1319 (2007).
25. Oishi, M., Chiba, K., Malhotra, B. and Suwa, T.: Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab. Dispos., 38: 1456-1463 (2010).
26. Neafsey, P., Ginsberg, G., Hattis, D. and Sonawane, B.: Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J. Toxicol. Environ. Health B Crit. Rev., 12: 334-361 (2009).
27. Zhen, Y., Slanar, O., Krausz, K. W., Chen, C., Slavik, J., McPhail, K. L., Zabriskie, T. M., Perlik, F., Gonzalez, F. J. and Idle, J. R.: 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Drug Metab. Dispos., 34: 1563-1574 (2006).
28. Ingelman-Sundberg, M., Sim, S. C., Gomez, A. and Rodriguez-Antona, C.: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 116: 496-526 (2007).
29. Lee, S. J., Lee, S. S., Jung, H. J., Kim, H. S., Park, S. J., Yeo, C. W. and Shin, J. G.: Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab. Dispos., 37: 1464-1470 (2009).
30. Dickinson, G. L., Rezaee, S., Proctor, N. J., Lennard, M. S., Tucker, G. T. and Rostami-Hodjegan, A.: Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J. Clin. Pharmacol., 47: 175-186 (2007).
31. Dorne, J. L., Walton, K., Slob, W. and Renwick, A. G.: Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem. Toxicol., 40: 1633-1656 (2002).
32. Ishiguro, A., Kubota, T., Ishikawa, H. and Iga, T.: Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity. Clin. Chim. Acta, 344: 201-204 (2004).
33. Tateishi, T., Chida, M., Ariyoshi, N., Mizorogi, Y., Kamataki, T. and Kobayashi, S.: Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther., 65: 570-575 (1999).
34. Naveen, A. T., Prasanna, T., Farzana, B. L., Rajan, S. and Adithan, C.: CYP2D6 genotype and phenotype relationship in South Indians. J. Postgrad. Med., 52: 253-256 (2006).
35. Kubota, T., Yamaura, Y., Ohkawa, N., Hara, H. and Chiba, K.: Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan Odemethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol., 50: 31-34 (2000).
36. Sachse, C., Brockmoller, J., Bauer, S. and Roots, I.: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 60: 284-295 (1997).
37. Cai, W. M., Chen, B. and Zhang, W. X.: Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clin. Pharmacol. Ther., 81: 95-98 (2007).
38. Olsson, B., Brynne, N., Johansson, C. and Arnberg, H.: Food increases the bioavailability of tolterodine but not effective exposure. J. Clin. Pharmacol., 41: 298-304 (2001).
39. Chalon, S. A., Desager, J. P., Desante, K. A., Frye, R. F., Witcher, J., Long, A. J., Sauer, J. M., Golnez, J. L., Smith, B. P., Thomasson, H. R. and Horsmans, Y.: Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin. Pharmacol. Ther., 73: 178-191 (2003).
40. Belle, D. J., Ernest, C. S., Sauer, J. M., Smith, B. P., Thomasson, H. R. and Witcher, J. W.: Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J. Clin. Pharmacol., 42: 1219-1227 (2002).
41. Sauer, J. M., Long, A. J., Ring, B., Gillespie, J. S., Sanburn, N. P., DeSante, K. A., Petullo, D., VandenBranden, M. R., Jensen, C. B., Wrighton, S. A., Smith, B. P., Read, H. A. and Witcher, J. W.: Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J. Pharmacol. Exp. Ther., 308: 410-418 (2004).
42. Nakagami, T., Yasui-Furukori, N., Saito, M., Tateishi, T. and Kaneo, S.: Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of Pglycoprotein in risperidone disposition. Clin. Pharmacol. Ther., 78: 43-51 (2005).
43. Brynne, N., Dalen, P., Alvan, G., Bertilsson, L. and Gabrielsson, J.: Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin. Pharmacol. Ther., 63: 529-539 (1998).
44. Huang, M. L., Van Peer, A., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A., Zylicz, Z., Visscher, H. W. and Jonkman, J. H.: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther., 54: 257-268 (1993).
45. Dalén, P., Dahl, M. L., Eichelbaum, M., Bertilsson, L. and Wilkinson, G. R.: Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics, 9: 697-706 (1999).
46. Yue, Q. Y., Zhong, Z. H., Tybring, G., Dalen, P., Dahl, M. L., Bertilsson, L. and Sjoqvist, F.: Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther., 64: 384-390 (1998).
47. Otani, M., Fukuda, T., Naohara, M., Maune, H., Senda, C., Yamamoto, I. and Azuma, J.: Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur. J. Clin. Pharmacol., 59: 395-399 (2003).
48. Bergmann, T. K., Bathum, L. and Brosen, K.: Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Eur. J. Clin. Pharmacol., 57: 123-127 (2001).